Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Pancreatic Cancer; Azeliragon Was Discovered By And Originally Under Development For Alzheimer's Disease By vtv Therapeutics, Which Cantex Licensed Worldwide Rights
Portfolio Pulse from Benzinga Newsdesk
Cantex Pharmaceuticals has received FDA Orphan Drug Designation for azeliragon for the treatment of pancreatic cancer. Azeliragon was originally developed by vtv Therapeutics for Alzheimer's disease and is now licensed to Cantex.
May 20, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
vtv Therapeutics, which originally developed azeliragon for Alzheimer's disease, may see positive sentiment due to the FDA Orphan Drug Designation granted to Cantex Pharmaceuticals for azeliragon in treating pancreatic cancer.
The FDA Orphan Drug Designation for azeliragon, originally developed by vtv Therapeutics, is likely to generate positive sentiment for VTVT as it highlights the potential of their drug in a new therapeutic area.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70